FOR IMMEDIATE RELEASE
SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore
RANCHO CORDOVA, Ca. (May 6, 2024) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, will unveil advancements in gene and cell therapy manufacturing through eightresearch poster presentations at the upcoming annual meeting of the American Society of Gene and Cell Therapy (ASGCT) to be held in Baltimore May 7-11.
SK pharmteco will present a range of innovative posters that showcase advancements in viral vector production, novel cell lines, plasmid quantification, and more.
“At SK pharmteco, innovation is in our DNA, and we’re relentlessly dedicated to improving patient lives through cell and gene therapies,” said John Lee, Global Head of Cell & Gene Therapy. “Our expertise empowers us to streamline development processes, accelerating the path to market for these groundbreaking treatments. We’re honored to present research that has the potential to unlock a new era of gene-based therapies, bringing hope to patients faster.”
SK pharmteco’s presentations, scheduled across multiple sessions throughout the conference, are as follows:
Wednesday, May 8, Noon – 7 pm ET
Improvements in AAV and Lenti-Viral Vector Production using the Mirus RevIt™ AAV Enhancer and VirusGen® LV Transfection Reagent and Kit.
Presenter: Brian Tomkowicz, PhD, SK pharmteco
Poster number: 451
Development of a Universal, GMP-ready, Clonal HEK293 Cell Line for the Manufacturing of Adeno-Associated Virus, Lenti- and Adenoviral Vectors.
Presenter: Brian Tomkowicz, PhD, SK pharmteco
Poster number: 452
Quantification of Plasmid Copy Number of Escherichia coli (E. coli) Master Cell Bank by Digital PCR.
Presenter: Syam Pillai, SK pharmteco
Poster number: 902
Thursday, May 9, 2024, Noon – 7 pm ET
Adapting a Replication Competent Adeno-Associated Virus (rcAAV) Assay for Commercial Manufacturing.
Presenter: Brian Tomkowicz, PhD, SK pharmteco
Poster number: 962
To read the accompanying white paper click here.
Friday, May 10, 2024, Noon – 7 pm
Orientation of Plasmid Origin of Replication (Ori) and its Impact on Inverted Terminal Repeat (ITR) Stability.
Presenter: Brian Tomkowicz, PhD, SK pharmteco
Poster number: 1424
A Comparison Study of Orthogonal Assays, Mass Photometry, SV-AUC, and Absorbance, ELISA and dPCR to estimate empty full AAV particles.
Presenter: Brian Tomkowicz, PhD, SK pharmteco
Poster number: 1425
Assessing the Impact of Adeno-Associated Virus (AAV) Production, Residual DNA Packaging, and Potency Between msDNA vs Plasmid DNA Formats.
Presenter: Brian Tomkowicz, PhD, SK pharmteco
Poster number: 1426
Efficient Separation of Plasmid Isoforms Using Anion Exchange Chromatography (AEX) and by Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF).
Presenter: Syam Pillai, SK pharmteco
Poster number: 1857
To view abstracts and additional information, visit: https://annualmeeting.asgct.org.
###
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapies. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group. For more on SK pharmteco, visit skpharmteco.com.
Contact:
Keith Bowermaster, APR, CCMP
keith.bowermaster@skpt.com
